Compare Enovix Corporation (ENVX) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Mesoblast Limited — how do they compare? Enovix Corporation trades at $2.56 (market cap $561.79M), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Mesoblast Limited is far larger — about 3.2× Enovix Corporation's market cap, and Mesoblast Limited is more actively traded (240,620 versus 5,898,906). Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Mesoblast Limited for 14 Days on average.
| ENVX | MESO | |
|---|---|---|
Market Cap | $561.79M | $1.81B |
Volume | 5,898,906 | 240,620 |
Sector | Industrials | Health |
52-Week High | $13.19 | $20.96 |
52-Week Low | $2.50 | $13.19 |
Typical Hold Time | 11 Days | 14 Days |
Enterprise Value | $623.49M | $1.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.55, down 5.56% today, reflecting ongoing investor concerns despite recent earnings beats. The stock shows bearish technical signals with negative moving averages and oscillators. Fundamentally, the company continues to burn cash with a net income margin of -473.89% in 2026, though revenue growth remains positive at 32% year-over-year. Recent CEO transition and strategic focus on defense battery manufacturing create uncertainty about execution.
The outlook remains challenging with significant cash burn and negative profitability, though analyst consensus is bullish with a $10.75 price target representing 321% upside. Key risks include execution challenges, high cash consumption, and competitive pressures in the battery sector. The company's $552 million cash position provides runway but requires successful commercialization to justify valuation.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
